OOC

CN Bio Raises $21 Million USD in First Close of Series B Investment Round

Retrieved on: 
Tuesday, April 23, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Health Technology, FDA, DSM-IV codes, NASH, Therapy, Patient, OOC, Toxicology, Drug discovery, Series, Growth, Pharmaceutical industry

CN Bio, a leading provider of single- and multi-organ microphysiological systems, today announced it has raised a $21 million investment in the first close of its Series B fundraising round.

Key Points: 
  • CN Bio, a leading provider of single- and multi-organ microphysiological systems, today announced it has raised a $21 million investment in the first close of its Series B fundraising round.
  • The funding has been secured from several new investors; including $10 million from Bayland Capital, and $5.5 million from founding shareholder, CN Innovations Holdings Ltd.
  • The investment will be used to accelerate the Company’s expanding product portfolio and to scale the business to support commercial expansion across key global markets.
  • CN Bio has taken key steps to build a team with extensive industry expertise and robust networks across the industry, with a longstanding track record of success.

Findhelp Partners with State of Missouri to Support Families with Young Children

Retrieved on: 
Thursday, April 4, 2024
OOC, Child care, Apple, Parent, Elementary, Teacher, Poverty, The Missourians, Privacy, State

According to the most recent U.S. Census, 19.3% of children under 5 years of age in Missouri live in poverty, and the Missouri Family Resources database & website (powered by Findhelp) will support more than 250,000 families in addition to state and local navigators who work on-the-ground in communities across Missouri.

Key Points: 
  • According to the most recent U.S. Census, 19.3% of children under 5 years of age in Missouri live in poverty, and the Missouri Family Resources database & website (powered by Findhelp) will support more than 250,000 families in addition to state and local navigators who work on-the-ground in communities across Missouri.
  • Findhelp works with 7,837 listed programs serving the state, including 4,318 programs focused on serving children and families.
  • "We are grateful to the Missouri Department of Elementary and Secondary Education for choosing us to help support children under 5 and their families," said Erine Gray, Founder and CEO of Findhelp.
  • "We're proud to partner with the State to help uplift Missouri families with young children and connect them to the resources they need to thrive."

CN Bio PhysioMimix Organ-on-a-Chip Data Supports Inipharm’s INI-822 for Metabolic Liver Disease Treatment Now in Clinical Testing

Retrieved on: 
Monday, December 4, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Molecule, OOC, Research, DSM-IV codes, Non-alcoholic fatty liver disease, Prevalence, MPS, Hepatology, Patient, Therapy, Drug discovery, NIAB, HSD17B13, NASH, Pharmaceutical industry

The use of in vitro OOC for early evidence of efficacy for INI-822 demonstrates the transformative potential of these models to provide human-relevant data within preclinical programmes.

Key Points: 
  • The use of in vitro OOC for early evidence of efficacy for INI-822 demonstrates the transformative potential of these models to provide human-relevant data within preclinical programmes.
  • Loss-of-function variants of this gene are known to be associated with reduced incidence risk and severity of multiple liver diseases.
  • As part of the recent regulatory submission, CN Bio’s Contract Research Services team utilised the Company’s PhysioMimix OOC Systems and NASH ‘in-a-box' (NIAB) kit to generate critical data to determine compound efficacy.
  • For more information, visit: https://cn-bio.com/
    Inipharm Initiates Dosing in Phase 1 Study of Its Small Molecule Inhibitor of HSD17B13: https://www.businesswire.com/news/home/20231130655005/en/
    View source version on businesswire.com: https://www.businesswire.com/news/home/20231204544807/en/

CN Bio Wins ‘Most Impactful Industry Collaboration of the Year’ at the OBN Awards 2023 for Ongoing Research With the FDA

Retrieved on: 
Thursday, November 23, 2023
Research, FDA, Clinical Trials, Professional Services, Biotechnology, Health, Data Analytics, Pharmaceutical, Science, OOC, Reproducibility, Food, MPS, Government, Clinical and Translational Science, Patient, North American Menopause Society, Research fellow, Mills & Reeve, Drug discovery, Partnership, Human, NAM, Metabolism, Publication, Pharmaceutical industry

CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), has received the ‘Most Impactful Industry Collaboration of the Year’ at the 2023 OBN Awards.

Key Points: 
  • CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), has received the ‘Most Impactful Industry Collaboration of the Year’ at the 2023 OBN Awards.
  • Around 90% of drug candidates reaching clinical trials fail, often due to poor clinical translatability between conventional animal models and humans.
  • Recent ground-breaking legislature, including the US Government’s FDA Modernization Act and similar acts from the Canadian Government have supported this.
  • Dr. Tomasz Kostrzewski, Chief Scientific Officer, commented: “It is a huge honour to have received Most Impactful Industry Collaboration of the Year at this year’s OBN Awards.

HSS Presents New Reproductive Health Research at the ACR Convergence 2023

Retrieved on: 
Tuesday, November 14, 2023
Knowledge, Woman, Cervical cancer, Contraindication, Patient, Rheumatoid arthritis, Documentation, SLE, Infertility, Diagnosis, Rheumatology, Rheumatism, Fertility, Prevalence, Menopause, Vaccination, Cryopreservation, Flare, DSM-IV codes, Birth, Connective tissue, Hospital for Special Surgery, Doctor of Public Health, Female, Fetus, Smoking, Senior counsel, RD, SAN, Menstrual cycle, Weill Cornell Medicine, Immunosuppression, Risk, History, Hysterectomy, Inflammatory arthritis, Lupus, HSS, PAP, Fertilisation, OOC, Research, Human papillomavirus infection, Ageing, Scleroderma, Systemic scleroderma, Vaccine, American College, American College of Rheumatology, COVID-19, Fertility preservation, MPH, ACR, HPV, Hospital, Birth control, Nursing, Food delivery, MD

Additional research is planned to assess whether demographics, lifestyle and medical conditions may influence this potential association.

Key Points: 
  • Additional research is planned to assess whether demographics, lifestyle and medical conditions may influence this potential association.
  • This study surveyed women of reproductive age with systemic rheumatic disease about their use of contraceptives.
  • Data were collected on 249 women with reproductive capacity, including 147 with inflammatory arthritis and 102 with lupus-like disorders.
  • This study used data from the electronic health record of patients diagnosed with a rheumatic disease in adolescence, seen at HSS, to look at factors associated with HPV vaccination.

Casa Systems to Showcase Cloud-Native Technologies Delivering the Future of Broadband at SCTE Cable-Tec 2023

Retrieved on: 
Tuesday, October 17, 2023
Cloud, Investment, Fiber, DOCSIS 3.1, Cloud-Native Network Function, Extended-spectrum penicillin, HFC, OFDMA, MDT, FTTH, CO, IAC, OOC, ESD, SCTE, DOCSIS, Telecommunications, Television, Cable television

“With our vast experience across both wireline and wireless networking solutions, we are uniquely poised to help cable operators modernize their operations,” said Casa Systems’ CEO Michael Glickman. “SCTE Cable-Tec is the perfect venue for us to demonstrate how we can help cable providers open new revenue streams while simultaneously reducing their operating costs -- a double win for operators.”

Key Points: 
  • At this preeminent broadband telecommunications event, Casa Systems will exhibit an array of broadband solutions that accelerate the path to 10G, enable greater network capacity, deliver superior performance, and improve business agility for operators.
  • At the same time, Casa Systems’ solutions reduce operators’ total cost of ownership due to a consistently smaller footprint and reduced consumption of power compared to legacy solutions.
  • Casa Systems will showcase its full line of cloud-native solutions and network edge devices at SCTE Cable-Tec 2023, October 17-19 in Denver, CO, Booth #1613.
  • To schedule a meeting with Casa Systems’ broadband experts, please visit https://info.casa-systems.com/visit-casa-systems-at-cabletec-expo-2023-0-0 .

CN Bio Appoints Dr. Samantha Macro as Chief Financial Officer

Retrieved on: 
Tuesday, June 6, 2023
Biotechnology, Science, Health, Other Science, OOC, Aviva, PwC, Samantha, MBA, MPS, Doctor of Philosophy, AstraZeneca, CN, Sale, Horizon Discovery, PerkinElmer, Acquisition, Traction, CFO, Growth, Therapy, Management

CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced that it has appointed Dr. Samantha Macro as Chief Financial Officer.

Key Points: 
  • CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced that it has appointed Dr. Samantha Macro as Chief Financial Officer.
  • Samantha joins CEO, Dr. Paul Brooks, on the executive team to guide all key commercial and strategic initiatives, drive revenue and shape CN Bio’s ongoing growth trajectory.
  • Ahead of transitioning into life sciences, Samantha qualified as a chartered accountant at PwC and held senior roles at PwC and Aviva.
  • Dr. Samantha Macro, CFO, CN Bio, commented: “CN Bio’s OOC solutions are disruptive within the sector; capable of accurately and efficiently predicting human responses to medicines.

SparkCharge Expands Mobile EV Charging Fleet Service Nationwide

Retrieved on: 
Thursday, March 16, 2023
Eye, Capital expenditure, EV, Greenhouse gas emissions, Transport, Dominoes, Organization, USPS, OPEX, Running, OOC, Content as a service, Greenhouse gas, DHL, Car rental, Airline, Electric battery

SOMERVILLE, Mass., March 16, 2023 /PRNewswire/ -- SparkCharge, the first company to create a mobile EV charging system and network, today announced its new Charging as a Service (CaaS) option, SparkCharge Fleet, is now available nationwide to offer immediate charging access for businesses utilizing electric vehicles.

Key Points: 
  • SOMERVILLE, Mass., March 16, 2023 /PRNewswire/ -- SparkCharge , the first company to create a mobile EV charging system and network, today announced its new Charging as a Service (CaaS) option, SparkCharge Fleet , is now available nationwide to offer immediate charging access for businesses utilizing electric vehicles.
  • "SparkCharge Fleet is a solution that takes the guess work out of charging infrastructure and makes managing all aspects of EV fleet charging effortless," said Josh Aviv, founder and CEO of SparkCharge.
  • SparkCharge has created a cost-effective charging service by bundling CapEx, OpEx and energy costs into a fixed rate, enabling fleet operators to forecast and manage costs long-term.
  • SparkCharge also offers Out of Charge (OOC) , a commercial electric vehicle charging service that allows fleet operators to request on-demand EV charging when a vehicle is low or out of range.

CN Bio Appoints Deepak Singh as Vice President of Sales and Marketing

Retrieved on: 
Tuesday, March 14, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Marketing, PerkinElmer, Research, Legislation, Deepak, Union of Sales and Marketing Professionals, Affymetrix, MPS, Central London, CN, Pacific Biosciences, Horizon Discovery, OOC, Bachelor of Science, HT, Safety, FDA, Drug discovery, Applied Biosystems, Pharmaceutical industry, Fine chemical

CN Bio, a leading Organ-on-a-chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), has today announced that is has appointed Deepak Singh as Vice President of Sales and Marketing.

Key Points: 
  • CN Bio, a leading Organ-on-a-chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), has today announced that is has appointed Deepak Singh as Vice President of Sales and Marketing.
  • Prior to this, Deepak was with Pacific Biosciences as Vice President of EMEA Operations.
  • He also held senior-level sales and marketing positions at Affymetrix and the Genetic Analysis Unit of Applied Biosystems (formerly a PerkinElmer company).
  • Deepak Singh, VP Sales and Marketing at CN Bio, commented: “Having had extensive experience within the life science industry, I am excited by the possibilities of OOC technology, and how fast the potential of this technology is being realised.

CN Bio Extends Microphysiological System Portfolio With PhysioMimix Single-Organ Higher Throughput System

Retrieved on: 
Monday, February 27, 2023
Health, Health Technology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Tissue, Safety, CN, Immune system, SBS, Drug discovery, FDA, Toxicity, North American Menopause Society, Physiology, Hepatology, Culture, OOC, Environment, Hepatotoxicity, NASH, MPS, Non-alcoholic fatty liver disease, Pharmaceutical industry

CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced the commercial launch of the PhysioMimix™ Single-organ Higher Throughput (HT) System.

Key Points: 
  • CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced the commercial launch of the PhysioMimix™ Single-organ Higher Throughput (HT) System.
  • The PhysioMimix HT System provides users with a scalable solution, combining a significantly reduced cost-per-chip with increased run capacity.
  • The MPS enables users to culture primary human cells as 3D microtissues in a fully perfused microenvironment that incorporates key elements of the human immune system.
  • For more information on CN Bio’s PhysioMimix OOC range of products, please visit: https://cn-bio.com/physiomimix-ooc/